Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.70 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.68 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.68 |
| ▸ | LTA4H | P09960 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3260775 | 0.91 | HRH3 (0.71) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL20550862 | 0.85 | HRH3 (0.51) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL8430078 | 0.82 | HRH3 (0.72) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL2554940 | 0.82 | HRH3 (0.72) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL9935084 | 0.81 | CYP2D6 (0.66) | HRH3LTA4HKDM4EESR1CYP2D6 | |
| SCHEMBL11649743 | 0.81 | HRH3 (0.56) | HRH3LTA4HALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL4607528 | 0.81 | HRH3 (0.70) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL17974260 | 0.81 | HRH3 (0.70) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL14608491 | 0.81 | HRH3 (0.70) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL110426 | 0.81 | KEAP1 (1.00) | HRH3KEAP1NFE2L2LTA4HKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961231-B2 | NTCP inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-03-30 | — | — | US | disclosed |
| US-20210040072-A1 | NTCP Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-02-11 | — | — | US | disclosed |
| EP-3765482-A1 | NTCP INHIBITORS | National Institute Of Biological Sciences, Beijing (CN) | 2021-01-20 | — | — | EP | disclosed |
| CN-112218878-A | NTCP inhibitors | 北京生命科学研究所 | 2021-01-12 | — | — | CN | disclosed |
| WO-2020215267-A1 | USE OF NTCP INHIBITORS IN PREVENTING AND TREATING HEPATOCARCINOGENESIS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-10-29 | — | — | WO | disclosed |
| WO-2019196953-A1 | NTCP INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-10-17 | — | — | WO | disclosed |
| CN-106518706-A | Itopride preparation method | 安徽省诚联医药科技有限公司 | 2017-03-22 | — | — | CN | disclosed |
| EP-2401270-B1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2013-10-16 | — | — | EP | disclosed |
| EP-2401270-B1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| EP-1025077-B1 | NOVEL ARYLOXY-ALKYL-DIALKYLAMINES | WYETH CORP (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1025077-B1 | NOVEL ARYLOXY-ALKYL-DIALKYLAMINES | WYETH CORP (US) | 2007-02-28 | — | — | EP | disclosed |
| US-6268504-B1 | USED IN THE PRODUCTION OF PHARMACEUTICAL PRODUCTS | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-6242605-B1 | Aryloxy-alkyl-dialkylamines | AMERICAN HOME PRODUCTS CORPORATION | 2001-06-05 | — | — | US | disclosed |
| EP-1025077-A1 | NOVEL ARYLOXY-ALKYL-DIALKYLAMINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-09 | — | — | EP | disclosed |
| US-6005102-A | NOVEL INTERMEDIATES WHICH MAY BE USED IN THE PRODUCTION OF PHARMACEUTICAL COMPOUNDS FOR ANTI-ESTROGENIC AND MATRIX METALLOPROTEINASES-INHIBITING UTILITIES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-21 | — | — | US | disclosed |
| WO-1999019293-A1 | NOVEL ARYLOXY-ALKYL-DIALKYLAMINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0774966-A4 | BENZOFURAN COMPOUNDS, COMPOSITIONS, AND METHODS | LILLY CO ELI (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0774966-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS, AND METHODS | ELI LILLY AND COMPANY (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996009040-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS, AND METHODS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040072-A1 | NTCP Inhibitors | HAVCR2, NPC1, HMGCR | HRH3 3373/4885KEAP1 2142/4885NFE2L2 3783/4885 |
| US-10961231-B2 | NTCP inhibitors | HAVCR2, NPC1, HMGCR | HRH3 3373/4885KEAP1 2142/4885NFE2L2 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.